Elanco Animal HealthELAN
Recorded

Elanco Animal Health 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 7 minParticipants16

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good day, and welcome to Elanco Animal Health reports third quarter 2026 results. At this time, all participants are on listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question, you will need to press star 11 on your touchtone telephone. Please note, this call may be recorded. I would like to turn the call over to Tiffany Kanaga, Vice President of Investor Relations. Please go ahead. Good morning.

Tiffany KanagaVP of Investor Relations

Thank you for joining us for Elanco Animal Health third quarter 2026 earnings call. I am Tiffany Kanaga, Vice President of Investor Relations and ESG. Joining me on today's call are Jeff Simmons, our President and Chief Executive Officer, Bob VanHimbergen, our Chief Financial Officer, and Beth Haney from Investor Relations. The slides referenced during this call are available on the Investor Relations section of elanco.com. Today's discussion will include forward-looking statements. These statements are based on our current assumptions and expectations, and are subject to risks and uncertainties that could cause actual results to differ materially from our forecast. For more information, see the risk factors discussed in today's earnings press release, as well as in our latest Form 10-K and 10-Q filed with the SEC. We do not undertake any duty to update any forward-looking statements. Our remarks today will focus on our non-GAAP financial measures.

Tiffany KanagaVP of Investor Relations

Reconciliations of these non-GAAP measures are included in the appendix of today's slides and in the earnings press release. References to organic performance represent revenue growth excluding the impacts from royalty revenue and sales-based milestones that were sold to a third party, foreign exchange rates, and acquisitions and divestitures. After our prepared remarks, we will be happy to take your questions. I will now turn the call over to Jeff.

Jeff SimmonsPresident and CEO

Thanks, Tiffany. Good morning, everyone. Elanco delivered an outstanding third quarter, outperforming our commitments and growing revenue 11% on a reported basis, or 9% in organic constant currency. We are growing the right way, with accelerating price up 4% and volume up 5%, reflecting the value created by our basket of innovation and our diverse portfolio. This translated to significant gross margin expansion, up 300 basis points, and greater free cash flow, moving our net leverage ratio under the three times milestone. Growth, innovation, cash. We are consistently executing along these three priorities, powered by our balanced business profile, strategically built to produce results as industry and competition evolves. We are just getting started, with significant runway for share gains off a small base and large growing global markets. As highlighted on slide four, Elanco exceeded the high end of guidance for revenue, adjusted EBITDA, and adjusted EPS.

Jeff SimmonsPresident and CEO

Growth was led by international pet health, up 17%, and U.S. pet health, up 13%, with positive contributions from global farm animal. In the third quarter, we saw strong veterinarian and pet owner demand for what we believe is best medicine innovation that we are bringing to the table. Zenrelia once again led total Elanco growth, with Credelio Quattro also a major contributor. Both brands achieved record market share in the U.S. in September. Our Big Six, led by Zenrelia and Quattro, helped drive $328 million of third quarter revenue from innovation, up 40% year-over-year. We are raising our full-year innovation revenue target to $1.275 billion to reflect continued momentum for our basket of innovation on a stable base. Looking ahead, Elanco has entered into the final quarter of the year with continued momentum from a position of strength.

Jeff SimmonsPresident and CEO

We are meaningfully raising full-year guidance by fully passing through the third quarter beat. Moving into 2027, we anticipate building on this year's expected outperformance. We are recommitting to deliver our annual algorithm of mid-single-digit revenue growth, high single-digit adjusted EBITDA growth, and low double-digit adjusted EPS growth, creating sustainable value for our customers and our shareholders. Turning to slide five, we break down the third quarter's 9% underlying organic constant currency revenue growth. AHV International, our acquisition, which closed April 30, contributed about a point of growth not included in the organic rate, and it further strengthens our global ruminant position. U.S. pet health's 13% increase was led by our vet clinic sales of Quattro and Zenrelia, with good growth in vaccines and pain, and a strong overall price contribution.

Jeff SimmonsPresident and CEO

We are creating value for pet owners and the industry through our truly differentiated portfolio of innovation, driving market share and accelerating price gains in what we see as a responsible marketplace and competitive backdrop. We have observed some pockets of time-bound investments from competitors, which happens periodically in the animal health industry, consistent with past behavior. While these tactics may temporarily shift sales timing, our strength in the quarter, and especially in September, is evidence of the attractiveness of our portfolio, and there being no fundamental impact on the trajectory of our share gains and revenue from our innovative products. In U.S. retail year to date, we continue to see stable consumer demand for Seresto and the Advantage family. Third quarter Seresto sales were partially impacted by retailer inventory drawdown, while year-to-date consumption trends for the brand are slightly positive, smoothing out that dynamic.

Jeff SimmonsPresident and CEO

Zenrelia and Quattro continue to achieve very robust growth outside the vet clinic. Putting it all together, U.S. pet health achieved 13% growth, despite retail sales being slightly negative in the quarter. We expect our omnichannel leadership- New distribution points and OTC innovation to provide durable growth next year and beyond, allowing us to reach the one-third of pet owners that don't regularly visit the veterinarian. Moving to international pet health, we delivered 17% organic constant currency revenue growth, driven by Zenrelia and AdTab. Zenrelia is rapidly approaching blockbuster status in international pet health alone, with ample room to grow into key category leadership in the $850 million international derm market. U.S. farm animal increased 7% in the quarter, or 10% including AHV.

Jeff SimmonsPresident and CEO

Growth was led by cattle with good contributions from beef and dairy. For the rest of the portfolio, swine was positive, more than offsetting a decline in poultry vaccines. International farm animal grew 1% in organic constant currency, or 4% including AHV and FX, also reflecting strength in ruminants with notable demand in LATAM. Poultry and swine were negative in the quarter, but combined for positive year-to-date growth. Regional farm cycles may create incremental quarter-on-quarter volatility ahead, but our expectations for accelerating global protein consumption underpin long-term value for the business. Turning to slide seven, we delivered $328 million of innovation revenue in the third quarter, led by continued momentum for our Big Six in aggregate. We are raising our anticipated innovation contribution for 2026, and we are running ahead of our ambition to double the Big Six between 2025 and 2028.

Jeff SimmonsPresident and CEO

This accelerated pace of innovation sales reflects a competitive advantage in the marketplace that we expect to sustain. It is built on rapid globalization, medically differentiated products with low market share in large categories, our growing commercial strength, data-driven brand investments that are driving increasing brand loyalty, and differentiated distribution partnerships. Let us further discuss the progress of our major innovation products on slide seven, starting with Zenrelia. It is an accelerating success story, well exceeding our expectations across geographies, even as competition increases. The third quarter was Zenrelia's biggest yet in both the U.S. and international, with this special product providing its largest-ever contribution to total Elanco revenue dollar growth. Efficacy is the clear driver behind Zenrelia's momentum, creating substantial value for veterinarians and pet owners, and translating into strong growth and share gains. Market demand drove U.S. sales to more than double in the quarter versus last year.

Jeff SimmonsPresident and CEO

Vet clinic penetration climbed to approximately 19,000, or two-thirds of the total clinic base, with steady month-to-month gains, even as new competition entered. U.S. JAK market share improved seven points year-on-year, ending on a record high in September, driven by new users and sticky repeat orders, and increased penetration in existing clinics. The average U.S. sales per clinic increased 8% from Q2 to Q3, even with new clinics and a competitive entrant. Summing up the performance in the U.S., yes, this quarter was increasingly competitive, but Zenrelia's momentum is stronger than ever. Our expanded sales team is seeing interest in our differentiated medicine superseding marketplace noise. Our strategy is working, and we do not see that changing. Zenrelia grew even faster internationally than in the U.S. in the third quarter and year to date. Growth has accelerated in Europe, the market with three JAK1 products for the longest period.

Jeff SimmonsPresident and CEO

Notably, Zenrelia gained 10 share points in Europe in the first half of 2026, the latest available data. This is five times the competitive entrant, driven by higher customer satisfaction with the product. Zenrelia is now in 48 countries outside the U.S., all without label restrictions. We continue to drive significant share gains across key geographies. For example, Zenrelia has continued to build on its market-leading position in Brazil, and has also achieved over 40% share in Japan. Globally, efficacy remains the differentiator, creating this remarkable performance and long-term growth potential. On to our second derm innovation, Befrena. Demand continues to build. We have just opened up access to Befrena to all customers, so our sales team can sell to every clinic, including large corporate accounts.

Jeff SimmonsPresident and CEO

We expect to fill all outstanding orders by next week and to move Befrena from a phased launch to a full-scale national launch in the first quarter. Befrena is already showing what our derm portfolio can do together. About 20% of clinics which have purchased Befrena have never used Zenrelia, unlocking a new door for Zenrelia. On supply, we are now making Befrena continually, with more than 30 commercial batches produced. We have finished the manufacturing expansion and process scale-up, and our larger-scale test runs have gone well. Although Befrena did not materially contribute to Q3's 13% growth in U.S. pet health, we expect it to be a major revenue growth driver in 2027, with the potential to be the single largest contributor to U.S. pet health growth next year. Next, on Credelio Quattro. We are very pleased with another good quarter of dollar share gains and broad-spectrum dispensing sales from the U.S. clinics.

Jeff SimmonsPresident and CEO

Quattro's market share increased 9 points in Q3 year-over-year. We have continued aggressive clinic expansion, reaching about 55% of the U.S. base today, up 15 points since Q1. That is an increase of approximately 4,500 clinics in just two quarters, reflecting strong veterinarian and pet owner demand for the four dimensions of differentiation that make Quattro what we believe is best medicine. Like Zenrelia, Quattro exited the quarter with strength, as September was the largest month of Q3, reaching its highest market share ever. Strategic DTC efforts activated demand into the later months of what we see is becoming a prolonged season. Remember that ticks remain active as long as temperatures are above freezing.

Jeff SimmonsPresident and CEO

Speed of tick kill isn't just a clinical metric, it is a household safety requirement, and Quattro's exceptional speed is resonating strongly with pet owners. Quattro's momentum has carried through the typical seasonality to make this Elanco's largest U.S. pet health product, surpassing Seresto on a trailing four-quarter basis. We are just getting started, with very limited global share compared to the two incumbent franchises exceeding $1 billion each. There is ample room for many years of Credelio Quattro growth through market expansion, deeper clinic penetration, market share gains within the clinic, research demonstrating differentiation, and global expansion. There is a significant upside outside the U.S., which we expect to help Credelio family become our largest global product family ever. So far this year, Quattro is launched in Australia, Canada, and Japan.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day